Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766248 | 0.91 | FAAH (0.61) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3772454 | 0.91 | FAAH (0.75) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3769724 | 0.91 | FAAH (0.73) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3763272 | 0.90 | MAPT (0.72) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3770539 | 0.89 | FAAH (0.60) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3765717 | 0.89 | FAAH (0.60) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3761321 | 0.85 | FAAH (0.74) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3771872 | 0.82 | FAAH (0.56) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3761160 | 0.82 | FAAH (0.66) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3771739 | 0.82 | FAAH (0.60) | FAAHMAPTMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | claimed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | claimed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885MAPT 3805/4885MAPK1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.